Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis

Satoshi Yamasaki, Tsuyoshi Muta, Taiki Higo, Hirotake Kusumoto, Eiko Zaitsu, Toshihiro Miyamoto, Yoshinao Oda, Koichi Akashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A 64-year-old female was diagnosed with systemic amyloidosis associated with multiple myeloma. Bortezomib and dexamethasonetherapy was initiated; however, she developed lethal ventricular fibrillation (VF) and cardiac arrest after 84 hours of therapy. Cardiopulmonary resuscitation using direct current shocks with epinephrine and amiodarone was initiated but failed to receive cardiac function. Although her arterial pulsations recovered immediately after the injection of vasopressin, she died of heart failure 8 hours after the onset of VF. Cardiac amyloidosis was verified by autopsy. Although the direct association of bortezomib with lethal VF remained to be clarified in our patient, the current report emphasizes on bortezomib as a substantial risk factor for cardiomyocyte damage. The potential risk of lethal events associated with cardiac amyloidosis should be carefully considered during bortezomib treatment for patients with AL amyloidosis.

Original languageEnglish
Pages (from-to)39-42
Number of pages4
JournalHematology Reports
Volume5
Issue number3
DOIs
Publication statusPublished - Sep 16 2013

Fingerprint

Ventricular Fibrillation
Amyloidosis
Amiodarone
Cardiopulmonary Resuscitation
Therapeutics
Heart Arrest
Vasopressins
Multiple Myeloma
Cardiac Myocytes
Epinephrine
Autopsy
Shock
Heart Failure
Injections
Bortezomib

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis. / Yamasaki, Satoshi; Muta, Tsuyoshi; Higo, Taiki; Kusumoto, Hirotake; Zaitsu, Eiko; Miyamoto, Toshihiro; Oda, Yoshinao; Akashi, Koichi.

In: Hematology Reports, Vol. 5, No. 3, 16.09.2013, p. 39-42.

Research output: Contribution to journalArticle

@article{2887b57fcb1f4915b5e704957e17cdf6,
title = "Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis",
abstract = "A 64-year-old female was diagnosed with systemic amyloidosis associated with multiple myeloma. Bortezomib and dexamethasonetherapy was initiated; however, she developed lethal ventricular fibrillation (VF) and cardiac arrest after 84 hours of therapy. Cardiopulmonary resuscitation using direct current shocks with epinephrine and amiodarone was initiated but failed to receive cardiac function. Although her arterial pulsations recovered immediately after the injection of vasopressin, she died of heart failure 8 hours after the onset of VF. Cardiac amyloidosis was verified by autopsy. Although the direct association of bortezomib with lethal VF remained to be clarified in our patient, the current report emphasizes on bortezomib as a substantial risk factor for cardiomyocyte damage. The potential risk of lethal events associated with cardiac amyloidosis should be carefully considered during bortezomib treatment for patients with AL amyloidosis.",
author = "Satoshi Yamasaki and Tsuyoshi Muta and Taiki Higo and Hirotake Kusumoto and Eiko Zaitsu and Toshihiro Miyamoto and Yoshinao Oda and Koichi Akashi",
year = "2013",
month = "9",
day = "16",
doi = "10.4081/hr.2013.e12",
language = "English",
volume = "5",
pages = "39--42",
journal = "Hematology Reports",
issn = "2038-8322",
publisher = "PagePress",
number = "3",

}

TY - JOUR

T1 - Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis

AU - Yamasaki, Satoshi

AU - Muta, Tsuyoshi

AU - Higo, Taiki

AU - Kusumoto, Hirotake

AU - Zaitsu, Eiko

AU - Miyamoto, Toshihiro

AU - Oda, Yoshinao

AU - Akashi, Koichi

PY - 2013/9/16

Y1 - 2013/9/16

N2 - A 64-year-old female was diagnosed with systemic amyloidosis associated with multiple myeloma. Bortezomib and dexamethasonetherapy was initiated; however, she developed lethal ventricular fibrillation (VF) and cardiac arrest after 84 hours of therapy. Cardiopulmonary resuscitation using direct current shocks with epinephrine and amiodarone was initiated but failed to receive cardiac function. Although her arterial pulsations recovered immediately after the injection of vasopressin, she died of heart failure 8 hours after the onset of VF. Cardiac amyloidosis was verified by autopsy. Although the direct association of bortezomib with lethal VF remained to be clarified in our patient, the current report emphasizes on bortezomib as a substantial risk factor for cardiomyocyte damage. The potential risk of lethal events associated with cardiac amyloidosis should be carefully considered during bortezomib treatment for patients with AL amyloidosis.

AB - A 64-year-old female was diagnosed with systemic amyloidosis associated with multiple myeloma. Bortezomib and dexamethasonetherapy was initiated; however, she developed lethal ventricular fibrillation (VF) and cardiac arrest after 84 hours of therapy. Cardiopulmonary resuscitation using direct current shocks with epinephrine and amiodarone was initiated but failed to receive cardiac function. Although her arterial pulsations recovered immediately after the injection of vasopressin, she died of heart failure 8 hours after the onset of VF. Cardiac amyloidosis was verified by autopsy. Although the direct association of bortezomib with lethal VF remained to be clarified in our patient, the current report emphasizes on bortezomib as a substantial risk factor for cardiomyocyte damage. The potential risk of lethal events associated with cardiac amyloidosis should be carefully considered during bortezomib treatment for patients with AL amyloidosis.

UR - http://www.scopus.com/inward/record.url?scp=84884811645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884811645&partnerID=8YFLogxK

U2 - 10.4081/hr.2013.e12

DO - 10.4081/hr.2013.e12

M3 - Article

VL - 5

SP - 39

EP - 42

JO - Hematology Reports

JF - Hematology Reports

SN - 2038-8322

IS - 3

ER -